No.

Publication Date

Citing Article

1

2025

Amedeo Lonardo, Ralf Weiskirchen. Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon?, Exploration of Drug Science. 2025; 3: 1008128.  https://doi.org/10.37349/eds.2025.1008128

2

2026

Ralf Weiskirchen, Amedeo Lonardo. Treating obesity with GLP-1 RAs: does sex matter? A commentary on the meta-analysis by Yang et al. (J Diabetes 2025;17(3):e70063), Exploration of Endocrine and Metabolic Diseases. 2026; 3: 101458.  https://doi.org/10.37349/eemd.2026.101458

3

2025

Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz. Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide, Current Medical Research and Opinion. 2025; 41: 2089.  https://doi.org/10.1080/03007995.2025.2596430

4

2026

Mehdi Karimi, Seyed Morteza Ali Pourfaraji, Peyvand Parhizkar Roudsari, Samira Pirzad. Efficacy of Orlistat on Cardiometabolic Indices in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A GRADE-Assessed Systematic Review and Meta-Analysis of RCTs, Current Therapeutic Research. 2026; 104: 100822100822.  https://doi.org/10.1016/j.curtheres.2026.100822

5

2025

Amedeo Lonardo, Ralf Weiskirchen. PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD, Exploration of Digestive Diseases. 2025; 4: 100590.  https://doi.org/10.37349/edd.2025.100590

6

2026

Amedeo Lonardo, Ralf Weiskirchen. Mitochondrial medicine in obesity: a scoping review, Open Medicine. 2026; 21: 20261407.  https://doi.org/10.1515/med-2026-1407

7

2025

Ralf Weiskirchen, Amedeo Lonardo. Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders, Medical Sciences. 2025; 13: 265.  https://doi.org/10.3390/medsci13040265

8

2026

Hans-Theo Schon, Ralf Weiskirchen. Silent inflammation: a hidden cause of liver fibrosis, Frontiers in Pharmacology. 2026; 17: 1676534.  https://doi.org/10.3389/fphar.2026.1676534

9

2025

Amedeo Lonardo, Ralf Weiskirchen. Drug treatment of MASH from none to (too) many options?, Exploration of Medicine. 2025; 6: 1001378.  https://doi.org/10.37349/emed.2025.1001378

10

2026

Tianhao Wu, Mingyi Du, Tiejun Zhang, Xingdong Chen, Zhenqiu Liu. Comparisons of global incidence and risk factor profiles of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Annals of Hepatology. 2026; 31: 102139102139.  https://doi.org/10.1016/j.aohep.2025.102139

11

2025

Amedeo Lonardo, Ralf Weiskirchen. Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer, Biomolecules. 2025; 15: 1745.  https://doi.org/10.3390/biom15121745

12

2026

Mohamad Jamalinia, Ralf Weiskirchen, Amedeo Lonardo. Liver Fibrosis and the Risks of Impaired Cognition and Dementia: Mechanisms, Evidence, and Clinical Implications, Medical Sciences. 2026; 14: 44.  https://doi.org/10.3390/medsci14010044